Therapeutic potential of the drugs pioglitazone, nimodipine and ambroxol in Parkinson's disease

An integrative review.

Authors

DOI:

https://doi.org/10.18616/inova.v14i5.8568

Abstract

Introduction: Parkinson's disease (PD) is a neurodegenerative disease, with a chronic and progressive course, which is currently incurable. Current treatment is limited only to the palliative reduction of motor deficit aiming to improve the patient's quality of life. Objective: Using the drug repositioning strategy, the present study aimed to identify and evaluate new potential therapeutic indications for drugs used in practice clinical practice, which may act as PD-modifying agents. Method: A search was carried out in the PubMed, Scopus and Lilacs databases, in the last 5 years (2018-2023), using a combination of Boolean descriptors and operators, in English and Portuguese: (“Pioglitazone” OR “Ambroxol” OR “Nimodipine”) AND (“Neuroprotection” OR “Parkinson Disease”). Results: Pioglitazone, an oral antidiabetic, may have neuroprotective effects in PD, reducing inflammation and neuronal death. Ambroxol, a mucolytic agent, has been shown to be effective in reducing oxidative stress and neuroinflammation in PD. Nimodipine, currently used in the prophylaxis and treatment of neurological ischemia, may have neuroprotective effects in PD, attenuating neuronal death. Conclusion: Repurposing medications can be a viable therapeutic strategy for PD, and the aforementioned drugs show promise for treating the condition. Keywords: Parkinson's disease, neuroprotection, pioglitazone, ambroxol, nimodipine.

Downloads

Download data is not yet available.

Published

2024-06-28